Pharmafile Logo
Pharmafocus logo
Advanced Search

Sanofi

Showing 15 posts of 552 posts found.

covid_cell_1

Pharmafile.com’s weekly COVID-19 news round-up

November 4, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, GSK, Sanofi, UK, US, remdesivir

As European nations fall one by one back into lockdown, hopes weigh heavily on a vaccine to pave a path …

News
shutterstock_273326141

Sanofi angles to buy Kiadis for €308 million

November 2, 2020
Sales and Marketing Sanofi, kiadis, pharma

Sanofi has announced it is poised to buy out Amsterdam-based biopharma firm Kiadis in an all-cash public offer of €308 …

News
vaccination-1215279_960_720

GSK and Sanofi promise 200m COVID-19 vaccines to international COVAX initiative

October 28, 2020
Manufacturing and Production, Research and Development COVAX, COVID-19, GSK, Sanofi

Sanofi and GSK have committed 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine to the COVAX Facility, a …

News
sanofi_hq__boetie_hall_web

Sanofi’s Dupixent shows strength at Phase 3 in eosinophilic esophagitis

October 27, 2020
Manufacturing and Production Dupixent, Sanofi, pharma

Sanofi has lifted the curtain on new Phase 3 data for Dupixent (dupilumab), showing that the drug met all of …

News
sanofi_hq__boetie_hall_web

Sanofi’s Dupixent chalks up CHMP recommendation for paediatric severe atopic dermatitis

October 19, 2020
Sales and Marketing Dupixent, EMA, Sanofi, atopic dermatitis

Sanofi’s interleukin-4 and -13 inhibitor Dupixent (dupilumab) has been given the recommendation of the European Medicines Agency’s Committee for Medicinal …

News
nice_new_london_office_internal_3_web

NICE approves Sanofi’s Sarclisa combo for relapsed/refractory multiple myeloma

October 16, 2020
Medical Communications, Sales and Marketing NICE, Sanofi, Sarclisa, multiple myeloma

Sanofi’s Sarclisa (isatuximab) has secured a recommendation from NICE for routine use on the NHS in England and Wales as …

News
libtayo

Promising Phase 2 data for Sanofi and Regeneron’s PD-1 inhibitor Libtayo in locally advanced basal cell carcinoma

September 18, 2020
Medical Communications, Research and Development Cancer, ESMO 2020, Libtayo, Regeneron, Sanofi, pharma

Promising Phase 2 data has been released at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 for Sanofi …

News
sanofi_hq__boetie_hall_web

Extension study reveals Dupixent’s benefit can last up to three years in moderate-to-severe asthma

September 8, 2020
Manufacturing and Production, Research and Development Dupixent, Sanofi, asthma, pharma

New findings have been revealed from an extension study of Sanofi’s interleukin-4 (IL-4) and interleukin-13 (IL-13) inhibitor Dupixent (dupilumab) in …

News
800px-sanofi_frankfurt_iph

President of Sanofi France expects COVID-19 vaccine to be priced below ten Euros

September 7, 2020
Sales and Marketing COVID-19, GSK, Sanofi

The President of Sanofi France expects the coronavirus vaccine it is developing with GlaxoSmithKline to be priced under 10 Euros.  …

News
800px-vaccine

Sanofi halts Phase 3 trial of Kevzara as a COVID-19 treatment

September 1, 2020
Manufacturing and Production COVID-19, Sanofi, Vaccine, pharma

Sanofi is halting clinical trials treating serious COVID-19 patients with its Kevzara drug after data on its efficacy proved inconclusive.The …

News
6127242068_23c80ef94f_b

Sanofi to buy Principia Biopharma for $3.4 billion

August 17, 2020
Sales and Marketing MS, Sanofi

Sanofi is set to buy California based Principia Biopharma in a deal that is worth $3.4 billion. This deal means …

News
sanofi_hq

Sanofi indicted on manslaughter charges over its epilepsy drug Depakine

August 4, 2020
Manufacturing and Production Sanofi, Vaccine

Sanofi is being investigated for manslaughter in France over the deaths of four babies whose mothers took its anti-epilepsy medication …

News
shutterstock_138095450

US Government commits $2.1bn to GSK and Sanofi’s COVID-19 vaccine candidate

July 31, 2020
Medical Communications, Research and Development COVID-19, GSK, Sanofi, US, Vaccine

The US Government has announced additional funding into Sanofi and GlaxSmithKline’s efforts to develop a recombinant protein-based vaccine to the …

News

Sanofi’s nirsevimab nails study goals for prevention of respiratory syncytial virus in infants

July 30, 2020
Research and Development Sanofi, nirsevimab, pharma

Sanofi’s nirsevimab met its goals in a Phase 2b study, the company has revealed, investigating its efficacy in the prevention …

News
shutterstock_359806121

UK Government secures 60 million doses of Sanofi and GSK’s COVID-19 vaccine

July 29, 2020
Research and Development, Sales and Marketing COVID-19, GSK, Sanofi, UK government, pharma

The UK Government has sealed another deal to procure an effective COVID-19 vaccine for its citizens, partnering up with Sanofi …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023